Sign In
Buy RGNX
$6.69
+0.170 (+2.61%)
At Close: Jun 03, 2026
REGENXBIO Inc. (RGNX) Q3 2025 Earnings Call Transcript
04:16pm, Thursday, 06'th Nov 2025
REGENXBIO Inc. ( RGNX ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Patrick Christmas - Executive VP & Chief Strategy and Legal Officer Curran Simpson - President, CEO & Di
Regenxbio (RGNX) Reports Q3 Loss, Beats Revenue Estimates
09:26am, Thursday, 06'th Nov 2025
Regenxbio (RGNX) came out with a quarterly loss of $1.2 per share versus the Zacks Consensus Estimate of a loss of $1.38. This compares to a loss of $1.17 per share a year ago.
REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
07:05am, Thursday, 06'th Nov 2025
RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026 Pivotal trial enrollment completed in October; confirmatory trial
Y Intercept Hong Kong Ltd Invests $1.45 Million in REGENXBIO Inc. $RGNX
03:40am, Monday, 03'rd Nov 2025
Y Intercept Hong Kong Ltd purchased a new position in shares of REGENXBIO Inc. (NASDAQ: RGNX) during the undefined quarter, according to the company in its most recent disclosure with the Securities a
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
07:05am, Thursday, 30'th Oct 2025
Patients treated with RGX-202 demonstrate consistent, robust microdystrophin expression and functional improvement compared to natural history in Phase I/II portion of AFFINITY DUCHENNE® trial suppo
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights
07:05am, Wednesday, 29'th Oct 2025
ROCKVILLE, Md. , Oct. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, November 6, at 8:00 a.m.
REGENXBIO to Participate in Upcoming Investor Conferences
07:05am, Wednesday, 15'th Oct 2025
ROCKVILLE, Md. , Oct. 15, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Chardan's 9th Annual Genetic Medicines Conferenc
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting
07:05am, Thursday, 09'th Oct 2025
ROCKVILLE, Md. , Oct. 9, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present interim data from the Phase II ALTITUDE® trial evaluating suprachoroidal delivery of s
REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD
07:05am, Monday, 06'th Oct 2025
Over 1,200 participants enrolled in ATMOSPHERE® and ASCENT® pivotal trials, representing largest global gene therapy program ever conducted Subretinal surabgene lomparvovec on track to be first gene
REGENXBIO Announces Presentation at the World Muscle Society
07:05am, Monday, 29'th Sep 2025
ROCKVILLE, Md. , Sept. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced Chief Medical Officer, Steve Pakola, M.D.
Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome
06:12am, Tuesday, 09'th Sep 2025
Regenxbio's RGX-121 gene therapy for Hunter syndrome is the main catalyst, with FDA approval targeted for February 2026. Recent clinical data shows RGX-121 can address neurological decline, a major un
REGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
02:05pm, Monday, 08'th Sep 2025
REGENXBIO Inc. (NASDAQ:RGNX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 11:30 AM EDT Company Participants Curran Simpson - President, CEO & Director Steve Pakola - Exec
Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome
08:29am, Saturday, 06'th Sep 2025
Regenxbio's RGX-121 for Hunter syndrome saw its FDA review delayed to February 8, 2026, but strong 12-month surrogate endpoint data supports its potential as a gene therapy. Late-stage Sura-vec trials
REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II
07:05am, Friday, 05'th Sep 2025
12-month pivotal data further demonstrate the ability of one-time RGX-121 treatment to improve outcomes for patients with MPS II >80% reduction in CSF levels of HS D2S6, key biomarker of MPS II brain
REGENXBIO to Participate in Upcoming Investor Conferences
07:05am, Thursday, 28'th Aug 2025
ROCKVILLE, Md. , Aug. 28, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: 2025 Wells Fargo Healthcare Conference 1x1 Inves
